Current Awareness

You have free access to this content

Current Awareness in Contrast Media and Molecular Imaging

Article first published online: 7 MAR 2007

DOI: 10.1002/cmmi.127

Issue

Contrast Media & Molecular Imaging

Contrast Media & Molecular Imaging

Volume 2, Issue 1, pages 59–66, January/February 2007

Additional Information

How to Cite

(2007), Current Awareness in Contrast Media and Molecular Imaging. Contrast Media Mol Imaging, 2: 59–66. doi: 10.1002/cmmi.127

Publication History

  1. Issue published online: 7 MAR 2007
  2. Article first published online: 7 MAR 2007

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (178K)

Current Awareness

  • 1. Reviews
  • CMR 2005: International Contrast Media Research Symposium 11-16 October 2005 Evian, France (Conference Abstracts). Contrast Media Mol Imaging 1, (2006)
  • Beauchesne P, Pedeux R, Soler C. Imaging malignant gliomas with 99mTc MIBI brain single-photon emission computed tomography. Curr Med Imaging Rev 2, 227-235 (2006)
  • Ben-Haim S, Israel O. PET/CT for atherosclerotic plaque imaging. Q J Nucl Med Mol Imaging 50, 53-60 (2006)
  • Bis KG, Shetty AN, Brewington S, Arpasi P, Kosuri R, Stein W, Lauer M, O'Neill W. Coronary 64-slice computed tomographic angiography models employing aortic root and selective catheter directed contrast enhancement in swine: Technical feasibility and preliminary results using 3D and 4D reconstructions. Int J Cardiovasc Imaging 22, 517-531 (2006)
  • Bottrill M, Nicholas LK, Long NJ. Lanthanides in magnetic resonance imaging. Chem Soc Rev 35, 557-571 (2006)
  • Brooks DJ, Piccini P. Imaging in Parkinson's disease: The role of monoamines in behavior. Biol Psychiatry 59, 908-918 (2006)
  • Caravan P. Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. Chem Soc Rev 35, 512-523 (2006)
  • Cropley VL, Fujita M, Innis RB, Nathan PJ. Molecular imaging of the dopaminergic system and its association with human cognitive function. Biol Psychiatry 59, 898-907 (2006)
  • Delgado-Bolton RC, Carreras JL, Perez-Casejon MJ. A systematic review of the efficacy of 18FDG PET in unknown primary tumors. Curr Med Imaging Rev 2, 215-225 (2006)
  • Henry PG, Adriany G, Deelchand D, Gruetter R, Marjanska M, Oz G, Seaquist ER, Shestov A, Ugurbil K. In vivo13C NMR spectroscopy and metabolic modeling in the brain: A practical perspective. Magn Reson Imaging 24, 527-539 (2006)
  • Langen KJ, Hamacher K, Weckesser M, Floeth F, Stoffels G, Bauer D, Coenen HH, Pauleit D. O-(2-[18F]fluoroethyl)-L-tyrosine: Uptake mechanisms and clinical applications. Nucl Med Biol 33, 287-294 (2006)
  • Shields AF. Positron emission tomography measurement of tumor metabolism and growth: Its expanding role in oncology. Mol Imaging Biol 8, 141-150 (2006)
  • Stokkel MPM, Duchateau CSJ, Dragoiescu C. The value of FDG-PET in the follow-up of differentiated thyroid cancer: A review of the literature. Q J Nucl Med Mol Imaging 50, 78-87 (2006)
  • Tanimoto A, Kuribayashi S. Application of superparamagnetic iron oxide to imaging of hepatocellular carcinoma. Eur J Radiol 58, 200-216 (2006)
  • Trattnig S, Pinker K, Ba-Ssalamah A, Nobauer-Huhmann IM. The optimal use of contrast agents at high field MRI. Eur Radiol 16, 1280-1287 (2006)
  • Tweedle MF. Adventures in multivalency - The Harry S Fischer Memorial Lecture, CMR 2005: Evian, France. Contrast Media Mol Imaging 1, 2-9 (2006)
  • Wink MH, Wijkstra H, De La Rosette JJMCH, Grimbergen CA. Ultrasound imaging and contrast agents: A safe alternative to MRI?. Minim Invasive Ther Allied Technol 15, 93-100 (2006)
  • Woods M, Woessner DE, Sherry AD. Paramagnetic lanthanide complexes as PARACEST agents for medical imaging. Chem Soc Rev 35, 500-511 (2006)
  • 2. General
  • Henness S, Keating GM. Gadofosveset. Drugs 66, 851-857 (2006)
  • Contrast Agents: 3. Chemistry
  • Aime S, Gianolio E, Uggeri F, Tagliapietra S, Barge A, Cravotto G. New paramagnetic supramolecular adducts for MRI applications based on non-covalent interactions between Gd(III)-complexes and β- or γ-cyclodextrin units anchored to chitosan. J Inorg Biochem 100, 931-938 (2006)
  • Allen MJ, Raines RT, Kiessling LL. Contrast agents for magnetic resonance imaging synthesized with ring-opening metathesis polymerization. J Am Chem Soc 128, 6534-6535 (2006)
  • Anderson EA, Isaacman S, Peabody DS, Wang EY, Canary JW, Kirshenbaum K. Viral nanoparticles donning a paramagnetic coat: Conjugation of MRI contrast agents to the MS2 capsid. Nano Lett 6, 1160-1164 (2006)
  • Goldman M, Johannesson H, Axelsson O, Karlsson M. Design and implementation of 13C hyperpolarization from para-hydrogen, for new MRI contrast agents. C R Chim 9, 357-363 (2006)
  • Laurent S, Vander Elst L, Muller RN. Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Media Mol Imaging 1, 128-137 (2006)
  • Lee H, Lee E, Kim DK, Jang NK, Jeong YY, Jon S. Antibiofouling polymer-coated superparamagnetic iron oxide nanoparticles as potential magnetic resonance contrast agents for in vivo cancer imaging. J Am Chem Soc 128, 7383-7389 (2006)
  • Lee HY, Jee HW, Seo SM, Kwak BK, Khang G, Cho SH. Diethylenetriaminepentaacetic acid-gadolinium (DTPA-Gd)-conjugated polysuccinimide derivatives as magnetic resonance imaging contrast agents. Bioconjug Chem 17, 700-706 (2006)
  • Livramento JB, Weidensteiner C, Prata MIM, Allegrini PR, Geraldes CFGC, Helm L, Kneuer R, Merbach AE, Santos AC, Schmidt P, Toth E. First in vivo MRI assessment of a self-assembled metallostar compound endowed with a remarkable high field relaxivity. Contrast Media Mol Imaging 1, 30-39 (2006)
  • Mishra A, Pfeuffer J, Mishra R, Engelmann J, Mishra AK, Ugurbil K, Logothetis NK. A new class of Gd-based DO3A-ethylamine-derived targeted contrast agents for MR and optical imaging. Bioconjug Chem 17, 773-780 (2006)
  • Paris J, Gameiro C, Humblet V, Mohapatra PK, Jacques V, Desreux JF. Auto-assembling of ditopic macrocyclic lanthanide chelates with transition-metal ions. Rigid multimetallic high relaxivity contrast agents for magnetic resonance Imaging. Inorg Chem 45, 5092-5102 (2006)
  • Pierre VC, Botta M, Aime S, Raymond KN. Tuning the coordination number of hydroxypyridonate-based gadolinium complexes: Implications for MRI contrast agents. J Am Chem Soc 128, 5344-5345 (2006)
  • Port M, Raynal I, Vander Elst L, Muller RN, Dioury F, Ferroud C, Guy A. Impact of rigidification on relaxometric properties of a tricyclic tetraazatriacetic gadolinium chelate. Contrast Media Mol Imaging 1, 121-127 (2006)
  • Querol M, Chen JW, Bogdanov AA. A paramagnetic contrast agent with myeloperoxidase-sensing properties. Org Biomol Chem 4, 1887-1895 (2006)
  • Raghunand N, Jagadish B, Trouard TP, Galons JP, Gillies RJ, Mash EA. Redox-sensitive contrast agents for MRI based on reversible binding of thiols to serum albumin. Magn Reson Med 55, 1272-1280 (2006)
  • Van Tilborg GAF, Mulder WJM, Deckers N, Storm G, Reutelingsperger CPM, Strijkers GJ, Nicolay K. Annexin A5-functionalized bimodal lipid-based contrast agents for the detection of apoptosis. Bioconjug Chem 17, 741-749 (2006)
  • Vasalatiy O, Zhao P, Zhang S, Aime S, Sherry AD. Catalytic effects of apoferritin interior surface residues on water proton exchange in lanthanide complexes. Contrast Media Mol Imaging 1, 10-14 (2006)
  • Zhu DH, White RD, Hardy PA, Weerapreeyakul N, Sutthanut K, Jay M. Biocompatible nanotemplate-engineered nanoparticles containing gadolinium: Stability and relaxivity of a potential MRI contrast agent. J Nanosci Nanotechnol 6, 996-1003 (2006)
  • 4. Technique
  • Ayyagari AL, Zhang X, Ghaghada KB, Annapragada A, Hu X, Bellamkonda RV. Long-circulating liposomal contrast agents for magnetic resonance imaging. Magn Reson Med 55, 1023-1029 (2006)
  • Boesen M, Jensen KE, Qvistgaard E, Danneskiold-Samsoe B, Thomsen C, Ostergaard M, Bliddal H. Delayed gadolinium-enhanced magnetic resonance imaging (dGEMRIC) of hip joint cartilage: Better cartilage delineation after intra-articular than intravenous gadolinium injection. Acta Radiol 47, 391-396 (2006)
  • Cabella C, Geninatti Crich S, Corpillo D, Barge A, Ghirelli C, Bruno E, Lorusso V, Uggeri F, Aime S. Cellular labeling with Gd(III) chelates: Only high thermodynamic stabilities prevent the cells acting as ‘sponges’ of Gd3+ ions. Contrast Media Mol Imaging 1, 23-29 (2006)
  • De Monye C, De Weert TT, Zaalberg W, Cademartiri F, Siepman DAM, Dippel DWJ, Van der Lugt A. Optimization of CT angiography of the carotid artery with a 16-MDCT scanner: Craniocaudal scan direction reduces contrast material-related perivenous artifacts. Am J Roentgenol 186, 1737-1745 (2006)
  • Dudeck O, Bogusiewicz K, Pinkernelle J, Gaffke G, Pech M, Wieners G, Bruhn H, Jordan A, Ricke J. Local arterial infusion of superparamagnetic iron oxide particles in hepatocellular carcinoma - A feasibility and 3.0 T MRI study. Invest Radiol 41, 527-535 (2006)
  • Essig M, Tartaro A, Tartaglione T, Pirovano G, Kirchin MA, Spinazzi A. Enhancing lesions of the brain: Intraindividual crossover comparison of contrast enhancement after gadobenate dimeglumine versus established gadolinium comparators. Acad Radiol 13, 744-751 (2006)
  • Hauth EAM, Stockamp C, Maderwald S, Muhler A, Kimmig R, Jaeger H, Barkhausen J, Forsting M. Evaluation of the three-time-point method for diagnosis of breast lesions in contrast-enhanced MR mammography. Clin Imaging 30, 160-165 (2006)
  • Heilmann M, Kiessling F, Enderlin M, Schad LR. Determination of pharmacokinetic parameters in DCE MRI - Consequence of nonlinearity between contrast agent concentration and signal intensity. Invest Radiol 41, 536-543 (2006)
  • Ichikawa T, Erturk SM, Araki T. Multiphasic contrast-enhanced multidetector-row CT of liver: Contrast-enhancement theory and practical scan protocol with a combination of fixed injection duration and patients' body-weight-tailored dose of contrast material. Eur J Radiol 58, 165-176 (2006)
  • Klessen C, Asbach P, Hein PA, Lembcke A, Bauknecht HC, Huppertz A, Nentwig T, Hamm B, Taupitz M. Whole-body MR angiography: Comparison of two protocols for contrast media injection. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 178, 484-490 (2006)
  • Leen E, Ceccotti P, Kalogeropoulou C, Angerson WJ, Moug SJ, Horgan PG. Prospective multicenter trial evaluating a novel method of characterizing focal liver lesions using contrast-enhanced sonography. Am J Roentgenol 186, 1551-1559 (2006)
  • Lim AKP, Patel N, Eckersley RJ, Goldin RD, Thomas HC, Cosgrove DO, Taylor-Robinson SD, Blomley MJK. Hepatic vein transit time of SonoVue: A comparative study with Levovist. Radiology 240, 130-135 (2006)
  • Madhuranthakam AJ, Hu HH, Kruger DG, Glockner JF, Riederer SJ. Contrast-enhanced MR angiography of the peripheral vasculature with a continuously moving table and modified elliptical centric acquisition. Radiology 240, 222-229 (2006)
  • Meckel S, Mekle R, Taschner C, Haller S, Scheffler K, Radue EW, Wetzel SG. Time-resolved 3D contrast-enhanced MRA with GRAPPA on a 1.5-T system for imaging of craniocervical vascular disease: Initial experience. Neuroradiology 48, 291-299 (2006)
  • Murayama Y, Weber B, Saleem KS, Augath M, Logothetis NK. Tracing neural circuits in vivo with Mn-enhanced MRI. Magn Reson Imaging 24, 349-358 (2006)
  • Nassenstein K, Waltering KU, Eggebrecht H, Schlosser T, Hunold P, Barkhausen J. MR coronary angiography with MS-325, a blood pool contrast agent: Comparison of an inversion recovery steady-state free precession with an inversion recovery fast low angle shot sequence in volunteers. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 178, 508-514 (2006)
  • Newman GC, Hospod FE, Patlak CS, Fain SE, Pulfer KA, Cook TD, O'Sullivan F. Experimental estimates of the constants relating signal change to contrast concentration for cerebral blood volume by T2 MRI. J Cereb Blood Flow Metab 26, 760-770 (2006)
  • Quaia E, Palumbo A, Rossi S, Degobbis F, Cernic S, Tona G, Cova M. Comparison of visual and quantitative analysis for characterization of insonated liver tumors after microbubble contrast injection. Am J Roentgenol 186, 1560-1570 (2006)
  • Raatschen HJ, Swain R, Shames DM, Fu Y, Boyd Z, Zierhut ML, Wendland MF, Misselwitz B, Weinmann HJ, Wolf KJ, Brasch RC. MRI tumor characterization using Gd-GlyMe-DOTA-perfluorooctyl-mannose-conjugate (Gadofluorine M™), a protein-avid contrast agent. Contrast Media Mol Imaging 1, 113-120 (2006)
  • Radjenovic A, Ridgway JP, Smith MA. A method for pharmacokinetic modelling of dynamic contrast enhanced MRI studies of rapidly enhancing lesions acquired in a clinical setting. Phys Med Biol 51, N187-N197 (2006)
  • Rist C, Nikolaou K, Kirchin MA, Van Gessel R, Bae KT, Von Ziegler F, Knez A, Winteryperger BJ, Reiser MF, Becker CR. Contrast bolus optimization for cardiac 16-slice computed tomography -Comparison of contrast medium formulations containing 300 and 400 milligrams of iodine per milliliter. Invest Radiol 41, 460-469 (2006)
  • Schima W, Hammerstingl R, Catalano C, Marti-Bonmati L, Rummeny EJ, Montero FT, Dirisamer A, Westermayer B, Bellomi M, Brisbois D, Chevallier P, Dobritz M, Drouillard J, Fraioli F, Jesus Martinez M, Morassut S, Vogl TJ. Quadruple-phase MDCT of the liver in patients with suspected hepatocellular carcinoma: Effect of contrast material flow rate. Am J Roentgenol 186, 1571-1579 (2006)
  • Shapiro MG, Atanasijevic T, Faas H, Westmeyer GG, Jasanoff A. Dynamic imaging with MRI contrast agents: Quantitative considerations. Magn Reson Imaging 24, 449-462 (2006)
  • Shiftan L, Neeman M. Kinetic analysis of hyaluronidase activity using a bioactive MRI contrast agent. Contrast Media Mol Imaging 1, 106-112 (2006)
  • Suzuki S, Furui S, Kuwahara S, Kaminaga T, Yamauchi T, Konno K, Yokoyama N, Isshiki T. Accuracy of attenuation measurement of vascular wall in vitro on computed tomography angiography -Effect of wall thickness, density of contrast medium, and measurement point. Invest Radiol 41, 510-515 (2006)
  • Terreno E, Botta M, Dastru W, Aime S. Gd-enhanced MR images of substrates other than water. Contrast Media Mol Imaging 1, 101-105 (2006)
  • Ui I, Okajo A, Endo K, Utsumi H, Matsumoto K. Importance of volume limitation for tissue redox status measurements using nitroxyl contrast agents: A comparison of X-band EPR bile flow monitoring (BFM) method and 300 MHz in vivo EPR measurement. J Magn Reson 181, 107-112 (2006)
  • Wagner A, Mahrholdt H, Thomson L, Hager S, Meinhardt G, Rehwald W, Parker M, Shah D, Sechtem U, Kim RJ, Judd RM. Effects of time, dose, and inversion time for acute myocardiol infarct size measurements based on magnetic resonance imaging-delayed contrast enhancement. J Am Coll Cardiol 47, 2027-2033 (2006)
  • Yoshikawa H, Azuma T, Sasaki K, Kawabata K, Umemura S. Dynamic and precise visualization of contrast agent in blood vessels with motion correction. Jpn J Appl Phys Pt 1 45, 4754-4760 (2006)
  • 5. Experimental
  • Boswell GW, Miles DR, Thiemann PA, Mesfin M. Population pharmacokinetics and bioavailability of motexafin gadolinium (Xcytrin®) in CD1 mice following intravenous and intraperitoneal injection. Invest New Drugs 24, 281-289 (2006)
  • Boutry S, Laurent S, Vander Elst L, Muller RN. Specific E-selectin targeting with a superparamagnetic MRI contrast agent. Contrast Media Mol Imaging 1, 15-22 (2006)
  • Dourado PMM, Tsutsui JM, Santos JMT, Aiello VD, Mathias W, Ramires JAF, Luz PL, Chagas ACP. Bioeffects of albumin-encapsulated microbubbles and real-time myocardial contrast echocardiography in an experimental canine model. Braz J Med Biol Res 39, 825-832 (2006)
  • Faranesh AZ, Kraitchman DL, McVeigh ER. Measurement of kinetic parameters in skeletal muscle by magnetic resonance imaging with an intravascular agent. Magn Reson Med 55, 1114-1123 (2006)
  • Kamino D, Hata J, Haruma K, Manabe N, Tanaka S, Chayama K. Real-time visualization and quantitation of canine gastric mucosal blood flow by contrast-enhanced ultrasonography. Scand J Gastroenterol 41, 856-861 (2006)
  • Lucidarme O, Kono Y, Corbeil J, Choi SH, Golmard JL, Varner J, Mattrey RF. Angiogenesis: Noninvasive quantitative assessment with contrast-enhanced functional US in murine model. Radiology 239, 730-739 (2006)
  • McCarville MB, Streck CJ, Dickson PV, Li CS, Nathwani AC, Davidoff AM. Angiogenesis inhibitors in a murine neuroblastoma model: Quantitative assessment of intratumoral blood flow with contrast-enhanced gray-scale US. Radiology 240, 73-81 (2006)
  • Menezes NM, Olear EA, Li X, Connolly SA, Zurakowski D, Foley M, Shapiro F, Jaramillo D. Gadolinium-enhanced MR images of the growing piglet skeleton: Ionic versus nonionic contrast agent. Radiology 239, 406-414 (2006)
  • Mulder WJM, Douma K, Koning GA, Van Zandvoort MA, Lutgens E, Daemen MJ, Nicolay K, Strijkers GJ. Liposome-enhanced MRI of neointimal lesions in the ApoE-KO mouse. Magn Reson Med 55, 1170-1174 (2006)
  • Rosen Y, Ramniceanu G, Margalit R, Grobgeld D, Eilam R, Degani H, Furman-Haran E. Vascular perfusion of human lung cancer in a rat orthotopic model using dynamic contrast-enhanced magnetic resonance imaging. Int J Cancer 119, 365-372 (2006)
  • Schnorr J, Wagner S, Abramjuk C, Drees R, Schink T, Schellenberger EA, Pilgrimm H, Hamm B, Taupitz M. Focal liver lesions: SPIO-, gadolinium-, and ferucarbotran-enhanced dynamic T1-weighted and delayed T2-weighted MR imaging in rabbits. Radiology 240, 90-100 (2006)
  • Steger-Hartmann T, Graham PB, Muller S, Schweinfurth H. Preclinical safety assessment of Vasovist (gadofosveset trisodium), a new magnetic resonance imaging contrast agent for angiography. Invest Radiol 41, 449-459 (2006)
  • Stieltjes B, Kulssmann S, Bock M, Umathum R, Mangalathu J, Letellier E, Rittgen W, Edler L, Krammer PH, Kauczor HU, Martin-Villalba A, Essig M. Manganese-enhanced magnetic resonance imaging for in vivo assessment of damage and functional improvement following spinal cord injury in mice. Magn Reson Med 55, 1124-1131 (2006)
  • Watanabe T, Radulovic J, Boretius S, Frahm J, Michaelis T. Mapping of the habenulo-interpeduncular pathway in living mice using manganese-enhanced 3D MRI. Magn Reson Imaging 24, 209-215 (2006)
  • 6. Applications
  • Alimenti A, Spahr L, Loubeyre P. Multidetector multiphase contrast-enhanced liver CT: Prospective study comparing two contrast material injection rates on vascular and liver parenchyma enhancement in patients with varied cirrhotic status. J Comput Assist Tomogr 30, 368-371 (2006)
  • Hahnel S, Nguyen-Trong TH, Rohde S, Hartmann M, Braun C, Sartor K, Heiland S. 3.0 Tesla contrast-enhanced MR angiography of carotid artery stents: In vitro measurements as compared with 1.5 Tesla. J Neuroradiol 33, 75-80 (2006)
  • Halavaara J, Breuer J, Ayuso C, Balzer T, Bellin MF, Blomqvist L, Carter R, Grazioli L, Hammerstingl R, Huppertz A, Jung G, Krause D, Laghi A, Leen E, Lupatelli L, Marsili L, Martin J, Pretorius ES, Reinhold C, Stiskal M, Stolpen AH. Liver tumor characterization: Comparison between liver-specific gadoxetic acid disodium-enhanced MRI and biphasic CT - A multicenter trial. J Comput Assist Tomogr 30, 345-354 (2006)
  • Ito M, Ogino H, Oshima H, Shiraki N, Shibamoto Y, Kasai H, Mase M, Kawamura Y, Miyati T. Evaluation of CH3-DTPA-Gd (NMS60) as a new MR contrast agent: Early phase II study in brain tumors and dual dynamic contrast-enhanced imaging. Magn Reson Imaging 24, 625-630 (2006)
  • Paetsch I, Jahnke C, Barkhausen J, Spuentrup E, Cavagna F, Schnackenburg B, Huber M, Stuber M, Fleck E, Nagel E. Detection of coronary stenoses with contrast enhanced, three-dimensional free breathing coronary MR angiography using the gadolinium-based intravascular contrast agent gadocoletic acid (B-22956). J Cardiovasc Magn Reson 8, 509-516 (2006)
  • Tresoldi S, Sardanelli F, Borzani I, Flor N, Cornalba G. Liver metastases on serial contrast-enhanced multidetector computed tomography examinations - Was the detection possible on previous examinations?. J Comput Assist Tomogr 30, 378-385 (2006)
  • Molecular Imaging: 7. Carbon
  • Barletta J, Karimi F, Langstrom B. Synthesis of [11C-carbonyl]hydroxyureas by a rhodium-mediated carbonylation reaction using [11C]carbon monoxide. J Label Compound Radiopharm 49, 429-436 (2006)
  • Cappelli A, Matarrese M, Moresco RM, Valenti S, Anzini M, Vomero S, Turolla EA, Belloli S, Simonelli P, Filannino MA, Fazio F. Synthesis, labeling, and biological evaluation of halogenated 2-quinolinecarboxamides as potential radioligands for the visualization of peripheral benzodiazepine receptors. Bioorg Med Chem 14, 4055-4066 (2006)
  • Chen SR, Feng DG. Novel parameter estimation methods for 11C-acetate dual-input liver model with dynamic PET. IEEE Trans Biomed Eng 53, 967-973 (2006)
  • Chen SR, Ho CL, Feng DG. Functional imaging techniques for the evaluation of hepatocellular carcinoma using dynamic 11C-acetate PET imaging. Curr Med Imaging Rev 2, 205-214 (2006)
  • Cho SY, Polster J, Engles JM, Hilton J, Abraham EH, Wahl RL. In vitro evaluation of adenosine 5′-monophosphate as an imaging agent of tumor metabolism. J Nucl Med 47, 837-845 (2006)
  • Frankle WG, Slifstein M, Gunn RN, Huang Y, Hwang DR, Darr EA, Narendran R, Abi-Dargham A, Laruelle M. Estimation of serotonin transporter parameters with 11C-DASB in healthy humans: Reproducibility and comparison of methods. J Nucl Med 47, 815-826 (2006)
  • Galldiks N, Kracht LW, Burghaus L, Thomas A, Jacobs AH, Heiss WD, Herholz K. Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. Eur J Nucl Med Mol Imaging 33, 516-524 (2006)
  • Ginovart N, Galineau L, Willeit M, Mizrahi R, Bloomfield PM, Seeman P, Houle S, Kapur S, Wilson AA. Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography. J Neurochem 97, 1089-1103 (2006)
  • Guiducci L, Jarvisalo MJ, Kiss J, Nagren K, Viljanen A, Naum AG, Gastaldelli A, Savunen T, Knuuti J, Salvadori PA, Ferrannini E, Nuutila P, Iozzo P. [11C]palmitate kinetics across the splanchnic bed in arterial, portal and hepatic venous plasma during fasting and euglycemic hyperinsulinemia. Nucl Med Biol 33, 521-528 (2006)
  • Hummerich R, Schulze O, Raedler T, Mikecz P, Reimold M, Brenner W, Clausen M, Schloss P, Buchert R. Inhibition of serotonin transport by (+)McN5652 is noncompetitive. Nucl Med Biol 33, 317-323 (2006)
  • Ichise M, Vines DC, Gura T, Anderson GM, Suomi SJ, Higley JD, Innis RB. Effects of early life stress on [11C]DASB positron emission tomography imaging of serotonin transporters in adolescent peer- and mother-reared rhesus monkeys. J Neurosci 26, 4638-4643 (2006)
  • Ishiwata K, Kawamura K, Yajima K, Tu QGL, Mori H, Shiba K. Evaluation of (+)-p-[11C]methylvesamicol for mapping σ1 receptors: A comparison with [11C]SA4503. Nucl Med Biol 33, 543-548 (2006)
  • Jensen SB, Olsen AK, Pedersen K, Cumming P. Effect of monoamine oxidase inhibition on amphetamine-evoked changes in dopamine receptor availability in the living pig: A dual tracer PET study with [11C]harmine and [11C]raclopride. Synapse 59, 427-434 (2006)
  • Jucaite A, Odano I, Olsson H, Pauli S, Halldin C, Farde L. Quantitative analyses of regional [11C]PE2I binding to the dopamine transporter in the human brain: A PET study. Eur J Nucl Med Mol Imaging 33, 657-668 (2006)
  • Kumar JSD, Majo VJ, Sullivan GM, Prabhakaran J, Simpson NR, Van Heertum RL, Mann JJ, Parsey RV. Synthesis and in vivo evaluation of [11C]SN003 as a PET ligand for CRF1 receptors. Bioorg Med Chem 14, 4029-4034 (2006)
  • Kumar JSD, Prabhakaran J, Erlandsson K, Majo VJ, Simpson NR, Pratap M, Van Heertum RL, Mann JJ, Parsey RV. Synthesis and in vivo evaluation of [O-methyl-11C](2R,4R)-4-hydroxy-2-[2-[2-[2-(3-methoxy)phenyl]ethyl]phenoxy]ethyl-1-methylpyrrolidine as a 5-HT2A receptor PET ligand. Nucl Med Biol 33, 565-574 (2006)
  • Mading P, Zessin J, Pleiss U, Fuchtner F, Wust F. Synthesis of a 11C-labelled taxane derivative by [1-11C]acetylation. J Label Compound Radiopharm 49, 357-365 (2006)
  • Morvan D, Demidem A, Guenin S, Madelmont JC. Methionine-dependence phenotype of tumors: Metabolite profiling in a melanoma model using L-[methyl-13C]methionine and high-resolution magic angle spinning 1H-13C nuclear magnetic resonance spectroscopy. Magn Reson Med 55, 984-996 (2006)
  • Parsey RV, Kent JM, Oquendo MA, Richards MC, Pratap M, Cooper TB, Arango V, Mann JJ. Acute occupancy of brain serotonin transporter by sertraline as measured by [11C]DASB and positron emission tomography. Biol Psychiatry 59, 821-828 (2006)
  • Ravert HT, Zhang Y, Horti A, Dannals RF. Radiosynthesis of the α4β2 nicotinic acetylcholine receptor ligand: 5-((1-[11C]-methyl-2-(S) pyrrolidinyl)methoxy)-2-chloro-3-((E)-2-(2-fluoropyridin-4-yl)vinyl)pyridine. J Label Compound Radiopharm 49, 459-462 (2006)
  • Shen J. 13C magnetic resonance spectroscopy studies of alterations in glutamate neurotransmission. Biol Psychiatry 59, 883-887 (2006)
  • Studenov AR, Jivan S, Lu J, Adam MJ, Jensen SB, O'Neil JP, Ding YS. An improved method for the radiosynthesis of [11C]d-threo-methylphenidate. J Label Compound Radiopharm 49, 455-458 (2006)
  • Thominiaux C, De Bruin B, Bramoulle Y, Hinnen F, Demphel S, Valette H, Bottlaender M, Besret L, Kassiou M, Dolle F. Radiosynthesis of (E)-N-(2-[11C]methoxybenzyl)-3-phenyl-acrylamidine, a novel subnanomolar NR2B subtype-selective NMDA receptor antagonist. Appl Radiat Isot 64, 348-354 (2006)
  • Thominiaux C, Dolle F, James ML, Bramoulle Y, Boutin H, Besret L, Gregoire MC, Valette H, Bottlaender M, Tavitian B, Hantraye P, Selleri S, Kassiou M. Improved synthesis of the peripheral benzodiazepine receptor ligand [11C]DPA-713 using [11C] methyl triflate. Appl Radiat Isot 64, 570-573 (2006)
  • Zhang JM, Tian JH, Wang WS, Liu BL. A new technique for labeling of [11C]-choline, a positron-emitting tracer for tumor imaging. J Radioanal Nucl Chem 267, 665-668 (2006)
  • Zhang MR, Ogawa M, Maeda J, Ito T, Noguchi J, Kumata K, Okauchi T, Suhara T, Suzuki K. [2-11C]isopropyl-, [1-11C]ethyl-, and [11C]methyl-labeled phenoxyphenyl acetamide derivatives as positron emission tomography ligands for the peripheral benzodiazepine receptor: Radiosynthesis, uptake, and in vivo binding in brain. J Med Chem 49, 2735-2742 (2006)
  • 8. Fluorine
  • Abdel-Jalil RJ, Ubele M, Ehrlichmann W, Voelter W, Machulla HJ. 1-[18F]fluoroethyleneglycol-2-nitroimidazoles, a new class of potential hypoxia PET markers. J Radioanal Nucl Chem 267, 557-560 (2006)
  • Andrieux A, Switsers O, Chajari MH, Jacob JH, Delozier T, Gervais R, Allouache N, Laurencon V, Henry-Amar M, Bardet S. Clinical impact of fluorine-18 fluorodeoxyglucose positron emission tomography in cancer patients - A comparative study between dedicated camera and dual-head coincidence gamma camera. Q J Nucl Med Mol Imaging 50, 68-77 (2006)
  • Aquino SL, Kuester LB, Muse VV, Halpern EF, Fischman AJ. Accuracy of transmission CT and FDG-PET in the detection of small pulmonary nodules with integrated PET/CT. Eur J Nucl Med Mol Imaging 33, 692-696 (2006)
  • Beer AJ, Haubner R, Wolf I, Goebel M, Luderschmidt S, Niemeyer M, Grosu AL, Martinez MJ, Wester HJ, Weber WA, Schwaiger M. PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging αvβ3 expression. J Nucl Med 47, 763-769 (2006)
  • Chen DL, Rosenbluth DB, Mintun MA, Schuster DP. FDG-PET imaging of pulmonary inflammation in healthy volunteers after airway instillation of endotoxin. J Appl Physiol 100, 1602-1609 (2006)
  • Chen W, Silverman DHS, Delaloye S, Czernin J, Kamdar N, Pope W, Satyamurthy N, Schiepers C, Cloughesy T. 18FDOPA PET imaging of brain tumors: Comparison study with 18FDG PET and evaluation of diagnostic accuracy. J Nucl Med 47, 904-911 (2006)
  • Cheng Z, Levi J, Xiong ZM, Gheysens O, Keren S, Chen XY, Gambhir SS. Near-infrared fluorescent deoxyglucose analogue for tumor optical imaging in cell culture and living mice. Bioconjug Chem 17, 662-669 (2006)
  • De Geus-Oei LF, Pieters GFFM, Bonenkamp JJ, Mudde AH, Bleeker-Rovers CP, Corstens FHM, Oyen WJG. 18FDG PET reduced unnecessary hemithyroidectomies for thyroid nodules with inconclusive cytologic results. J Nucl Med 47, 770-775 (2006)
  • Delbeke D, Coleman RE, Guiberteau MJ, Brown ML, Royal HD, Siegel BA, Townsend DW, Berland LL, Parker JA, Hubner K, Stabin MG, Zubal G, Kachelriess M, Cronin V, Holbrook S. Procedure guideline for tumor imaging with 18FDG PET/CT 1.0. J Nucl Med 47, 885-895 (2006)
  • Even-Sapir E, Lerman H, Gutman M, Lievshitz G, Zuriel L, Polliack A, Inbar M, Metser U. The presentation of malignant tumours and pre-malignant lesions incidentally found on PET-CT. Eur J Nucl Med Mol Imaging 33, 541-552 (2006)
  • Fischer BM, Olsen MWB, Ley CD, Klausen TL, Mortensen J, Hojgaard L, Kristjansen PEG. How few cancer cells can be detected by positron emission tomography? A frequent question addressed by an in vitro study. Eur J Nucl Med Mol Imaging 33, 697-702 (2006)
  • Floeth FW, Pauleit D, Sabel M, Reifenberger G, Stoffels G, Stummer W, Rommel F, Hamacher K, Langen KJ. 18F-FET PET differentiation of ring-enhancing brain lesions. J Nucl Med 47, 776-782 (2006)
  • Fueger BJ, Czernin J, Hildebrandt I, Tran C, Halpern BS, Stout D, Phelps ME, Weber WA. Impact of animal handling on the results of 18FDG PET studies in mice. J Nucl Med 47, 999-1006 (2006)
  • Gagel B, Reinartz P, Demirel C, Kaiser HJ, Zimny M, Piroth M, Pinkawa M, Stanzel S, Asadpour B, Hamacher K, Coenen HH, Buell U, Eble MJ. [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: A feasibility study. BMC Cancer 6, 51 (2006)
  • Herder GJM, Kramer H, Hoekstra OS, Smit EF, Pruim J, Van Tinteren H, Comans EF, Verboom P, Uyl-de-Groot CA, Welling A, Paul MA, Boers M, Postmus PE, Teule GJ, Groen HJ. Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: A Dutch cooperative randomized study. J Clin Oncol 24, 1800-1806 (2006)
  • Ide M. Cancer screening with FDG-PET. Q J Nucl Med Mol Imaging 50, 23-27 (2006)
  • Ishii K, Kono AK, Sasaki H, Miyamoto N, Fukuda T, Sakamoto S, Mori E. Fully automatic diagnostic system for early- and late-onset mild Alzheimer's disease using FDG PET and 3D-SSP. Eur J Nucl Med Mol Imaging 33, 575-583 (2006)
  • Jadvar H, Henderson RW, Conti PS. 2-deoxy-2-[18F]fluoro-D-glucose-positron emission tomography/computed tomography imaging evaluation of esophageal cancer. Mol Imaging Biol 8, 193-200 (2006)
  • Johnstrom P, Rudd JHF, Richards HK, Fryer TD, Clark JC, Weissberg PL, Pickard JD, Davenport AP. Imaging endothelin ETB receptors using [18F]-BQ3020: In vitro characterization and positron emission tomography (microPET). Exp Biol Med 231, 736-740 (2006)
  • Lang LX, Jagoda E, Ma Y, Sassaman MB, Eckelman WC. Synthesis and in vivo biodistribution of 18F labeled 3-cis-, 3-trans-, 4-cis-, and 4-trans-fluoroclohexane derivatives of WAY 100635. Bioorg Med Chem 14, 3737-3748 (2006)
  • Larson SM, Schwartz LH. 18FDG PET as a candidate for “qualified biomarker”: Functional assessment of treatment response in oncology. J Nucl Med 47, 901-903 (2006)
  • Mahy P, De Bast M, Gillart J, Labar D, Gregoire V. Detection of tumour hypoxia: Comparison between EF5 adducts and [18F]EF3 uptake on an individual mouse tumour basis. Eur J Nucl Med Mol Imaging 33, 553-556 (2006)
  • Nanni C, Zamagni E, Farsad M, Castellucci P, Tosi P, Cangini D, Salizzoni E, Canini R, Cavo M, Fanti S. Role of 18FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: Preliminary results. Eur J Nucl Med Mol Imaging 33, 525-531 (2006)
  • Okane K, Ibaraki M, Toyoshima H, Sugawara S, Takahashi K, Miura S, Shimosegawa E, Satomi J, Kitamura K, Satoh T. 18FDG accumulation in atherosclerosis: Use of CT and MR co-registration of thoracic and carotid arteries. Eur J Nucl Med Mol Imaging 33, 589-594 (2006)
  • Pelosi E, Pennone M, Deandreis D, Douroukas A, Mancini M, Bisi G. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site. Q J Nucl Med Mol Imaging 50, 15-22 (2006)
  • Pichika R, Easwaramoorthy B, Collins D, Christian BT, Shi BZ, Narayanan TK, Potkin SG, Mukherjee J. Nicotinic α4β2 receptor imaging agents - Part II. Synthesis and biological evaluation of 2-[18F] fluoro-3-[2-((S)-3-pyrrolinyl)methoxy]pyridine (18F-nifene) in rodents and imaging by PET in nonhuman primate. Nucl Med Biol 33, 295-304 (2006)
  • Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S, Peters LJ. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: A substudy of Trans-Tasman Radiation Oncology Group study 98.02. J Clin Oncol 24, 2098-2104 (2006)
  • Roger G, Saba W, Valette H, Hinnen F, Coulon C, Ottaviani M, Bottlaender M, Dolle F. Synthesis and radiosynthesis of [18F]FPhEP, a novel α4β2-selective, epibatidine-based antagonist for PET imaging of nicotinic acetylcholine receptors. Bioorg Med Chem 14, 3848-3858 (2006)
  • Sankaranarayanapillai M, Tong WP, Maxwell DS, Pal A, Pang JH, Bornmann WG, Gelovani JG, Ronen SM. Detection of histone deacetylase inhibition by noninvasive magnetic resonance spectroscopy. Mol Cancer Ther 5, 1325-1334 (2006)
  • Santiago JFY, Gonen M, Yeung H, Macapinlac H, Larson S. A retrospective analysis of the impact of 18FDG-PET scans on clinical management of 133 breast cancer patients. Q J Nucl Med Mol Imaging 50, 61-67 (2006)
  • Schmaljohann J, Guendisch D, Minnerop M, Bucerius J, Joe A, Reinhardt M, Guhlke S, Biersack HJ, Wuellner U. In vitro evaluation of nicotinic acetylcholine receptors with 2-[18F]F-A85380 in Parkinson's disease. Nucl Med Biol 33, 305-309 (2006)
  • Schoder H, Carslon DL, Kraus DH, Stambuk HE, Gonen M, Erdi YE, Yeung HWD, Huvos AG, Shah JP, Larson SM, Wong RJ. 18FDG PET/CT for detecting nodal metastases in patients with oral cancer staged NO by clinical examination and CT/MRI. J Nucl Med 47, 755-762 (2006)
  • Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, Larson S, Mankoff DA, Siegel BA, Van den Abbeele A, Yap J, Sullivan D. Consensus recommendations for the use of 18FDG PET as an indicator of therapeutic response in patients in National Cancer Institute trials. J Nucl Med 47, 1059-1066 (2006)
  • Smith-Jones PM, Solit D, Afroze F, Rosen N, Larson SM. Early tumor response to Hsp90 therapy using HER2 PET: Comparison with 18FDG PET. J Nucl Med 47, 793-796 (2006)
  • Spaeth N, Wyss MT, Pahnke J, Biollaz G, Lutz A, Goepfert K, Westera G, Treyer V, Weber B, Buck A. Uptake of 18F-fluorocholine, 18F-fluoro-ethyl-L-tyrosine and 18F-fluoro-2-deoxyglucose in F98 gliomas in the rat. Eur J Nucl Med Mol Imaging 33, 673-682 (2006)
  • Van Laere K, Nuttin B, Gabriels L, Dupont P, Rasmussen S, Greenberg BD, Cosyns P. Metabolic imaging of anterior capsular stimulation in refractory obsessive-compulsive disorder: A key role for the subgenual anterior cingulate and ventral striatum. J Nucl Med 47, 740-747 (2006)
  • Wadsak W, Wirl-Sagadin B, Mitterhauser M, Mien LK, Ettlinger DE, Keppler BK, Dudczak R, Kletter K. NCA nucleophilic radiofluorination on substituted benzaldehydes for the preparation of [18F] fluorinated aromatic amino acids. Appl Radiat Isot 64, 355-359 (2006)
  • Wadsak W, Mitterhauser M, Rendl G, Schuetz M, Mien LK, Ettlinger DE, Dudczak R, Kletter K, Karanikas G. [18F]FETO for adrenocortical PET imaging: A pilot study in healthy volunteers. Eur J Nucl Med Mol Imaging 33, 669-672 (2006)
  • Zeng FX, Southerland JA, Voll RJ, Votaw JR, Williams L, Cillax BJ, Levey AI, Goodman MM. Synthesis and evaluation of two 18F-labeled imidazo[1,2-a]pyridine analogues as potential agents for imaging β-amyloid in Alzheimer's disease. Bioorg Med Chem Lett 16, 3015-3018 (2006)
  • Zijlstra S, Gunawan J, Freytag C, Burchert W. Synthesis and evaluation of fluorine-18 labelled compounds for imaging of bacterial infections with PET. Appl Radiat Isot 64, 802-807 (2006)
  • 10. Hydrogen
  • Bartella L, Morris EA, Dershaw DD, Liberman L, Thakur SB, Moskowitz C, Guido J, Huang W. Proton MR spectroscopy with choline peak as malignancy marker improves positive predictive value for breast cancer diagnosis: Preliminary study. Radiology 239, 686-692 (2006)
  • Choi C, Coupland NJ, Bhardwaj PP, Malykhin N, Gheorghiu D, Allen PS. Measurement of brain glutamate and glutamine by spectrally-selective refocusing at 3 Tesla. Magn Reson Med 55, 997-1005 (2006)
  • Coon AL, Arias-Mendoza F, Colby GP, Cruz-Lobo J, Mocco J, Mack WJ, Komotar RJ, Brown TR, Connolly ES. Correlation of cerebral metabolites with functional outcome in experimental primate stroke using in vivo1H-magnetic resonance spectroscopy. Am J Neuroradiol 27, 1053-1058 (2006)
  • Epperson CN, Gueorguieva R, Czarkowski KA, Stiklus S, Sellers E, Krystal JH, Rothman DL, Mason GF. Preliminary evidence of reduced occipital GABA concentrations in puerperal women: A 1H-MRS study. Psychopharmacology (Berl) 186, 425-433 (2006)
  • Fayed N, Morales H, Modrego PJ, Pina MA. Contrast/noise ratio on conventional MRI and choline/creatine ratio on proton MRI spectroscopy accurately discriminate low-grade from high-grade cerebral gliomas. Acad Radiol 13, 728-737 (2006)
  • Larson-Meyer DE, Smith SR, Heilbronn LK, Kelley DE, Ravussin E, Newcomer BR. Muscle-associated triglyceride measured by computed tomography and magnetic resonance spectroscopy. Obesity 14, 73-87 (2006)
  • Lichy MP, Bachert P, Hamprecht F, Weber MA, Debus J, Schulz-Ertner D, Schlemmer HP, Kauczor HU. Application of 1H MR spectroscopic imaging in radiation oncology: Choline as a marker for determining the relative probability of tumor progression after radiation of glial brain tumors. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 178, 627-633 (2006)
  • Lin AP, Tran TT, Ross BD. Impact of evidence-based medicine on magnetic resonance spectroscopy. NMR Biomed 19, 476-483 (2006)
  • Lodi R, Pierangeli G, Tonon C, Cevoli S, Testa C, Bivona G, Magnifico F, Cortelli P, Montagna P, Barbiroli B. Study of hypothalamic metabolism in cluster headache by proton MR spectroscopy. Neurology 66, 1264-1266 (2006)
  • Mirza Y, O'Neill J, Smith EA, Russell A, Smith JM, Banerjee SP, Bhandari R, Boyd C, Rose M, Ivey J, Renshaw PF, Rosenberg DR. Increased medial thalamic creatine-phosphocreatine found by proton magnetic resonance spectroscopy in children with obsessive-compulsive disorder versus major depression and healthy controls. J Child Neurol 21, 106-111 (2006)
  • Ross AJ, Sachdev PS, Wen W, Brodaty H. Longitudinal changes during aging using proton magnetic resonance spectroscopy. J Gerontol A Biol Sci Med Sci 61, 291-298 (2006)
  • Sijens PE, Reijngoud DJ, Soorani-Lunsing RJ, Oudkerk M, Van Spronsen FJ. Cerebral 1H MR spectroscopy showing elevation of brain guanidino acetate in argininosuccinate lyase deficiency. Mol Genet Metab 88, 100-102 (2006)
  • Sjobakk TE, Lundgren S, Kristoffersen A, Singstad T, Svarliaunet AJ, Sonnewald U, Gribbestad IS. Clinical 1H magnetic resonance spectroscopy of brain metastases at 1.5T and 3T. Acta Radiol 47, 501-508 (2006)
  • Swanson MG, Zektzer AS, Tabatabai ZL, Simko J, Jarso S, Keshari KR, Schmitt L, Carroll PR, Shinohara K, Vigneron DB, Kurhanewicz J. Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy. Magn Reson Med 55, 1257-1264 (2006)
  • Tanaka Y, Obata T, Sassa T, Yoshitome E, Asai Y, Ikehira H, Suhara T, Okubo Y, Nishikawa T. Quantitative magnetic resonance spectroscopy of schizophrenia: Relationship between decreased N-acetylaspartate and frontal lobe dysfunction. Psychiatry Clin Neurosci 60, 365-372 (2006)
  • Tate AR, Underwood J, Acosta DM, Julia-Sape M, Majos C, Moreno-Torres A, Howe FA, Van der Graaf M, Lefournier V, Murphy MM, Loosemore A, Ladroue C, Wesseling P, Bosson JL, Cabanas ME, Simonetti AW, Gajewicz W, Calvar J, Capdevila A, Wilkins PR, Bell BA, Remy C, Heerschap A, Watson D, Griffiths JR, Arus C. Development of a decision support system for diagnosis and grading of brain tumours using in vivo magnetic resonance single voxel spectra. NMR Biomed 19, 411-434 (2006)
  • Terpstra M, Tkac I, Rao RL, Gruetter R. Quantification of vitamin C in the rat brain in vivo using short echo-time 1H MRS. Magn Reson Med 55, 979-983 (2006)
  • Venkatraman TN, Hamer RM, Perkins DO, Song AW, Lieberman JA, Steen RG. Single-voxel 1H PRESS at 4.0T: Precision and variability of measurements in anterior cingulate and hippocampus. NMR Biomed 19, 484-491 (2006)
  • Wang SJ, Lirng JF, Fuh JL, Chen JJ. Reduction in hypothalamic 1H-MRS metabolite ratios in patients with cluster headache. J Neurol Neurosurg Psychiatry 77, 622-625 (2006)
  • 11. Indium
  • Hanaoka H, Mukai T, Tamamura H, Mori T, Ishino S, Ogawa K, Iida Y, Doi R, Fujii N, Saji H. Development of a 111In-labeled peptide derivative targeting a chemokine receptor, CXCR4, for imaging tumors. Nucl Med Biol 33, 489-494 (2006)
  • Li C, Wang W, Wu QP, Shi K, Houston J, Sevick-Muraca E, Dong L, Chow D, Charnsangavej C, Gelovani JG. Dual optical and nuclear imaging in human melanoma xenografts using a single targeted imaging probe. Nucl Med Biol 33, 349-358 (2006)
  • Rodrigues M, Traub-Weidinger T, Li SR, Ibi B, Virgolini I. Comparison of 111In-DOTA-D Phe1-Tyr3-octreotide and 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 33, 532-540 (2006)
  • Tolmachev V, Nilsson FY, Widstrom C, Andersson K, Rosik D, Gedda L, Wennborg A, Orlova A. 111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. J Nucl Med 47, 846-853 (2006)
  • 12. Iodine
  • Amartey JK, Esguerra C, Al-Jammaz I, Parhar RS, Al-Otaibi B. Synthesis and evaluation of radioiodinated substituted β-naphthylalanine as a potential probe for pancreatic beta-cells imaging. Appl Radiat Isot 64, 769-777 (2006)
  • Baldwin RM, Zoghbi SS, Staley JK, Brenner E, Al-Tikriti MS, Amici L, Fujita M, Innis RB, Tamagnan G. Chemical fate of the nicotinic acetylcholinergic radiotracer [123I]5-IA-85380 in baboon brain and plasma. Nucl Med Biol 33, 549-554 (2006)
  • Booij J, De Bruin K, Gunning WB. Repeated administration of D-amphetamine induces loss of [123I]FP-CIT binding to striatal dopamine transporters in rat brain: A validation study. Nucl Med Biol 33, 409-411 (2006)
  • Catafau AM, Danus M, Bullich S, Llop J, Perich J, Cunningham VJ, Plaza P, Penengo MM, Eersels JLH, Squassante L, Ros D, Barbanoj M. Characterization of the SPECT 5-HT2A receptor ligand 123I-R91150 in healthy volunteers: Part 1—Pseudoequilibrium interval and quantification methods. J Nucl Med 47, 919-928 (2006)
  • Catafau AM, Danus M, Bullich S, Nucci G, Llop J, Abanades S, Cunningham VJ, Eersels JLH, Pavia J, Farre M. Characterization of the SPECT 5-HT2A receptor ligand 123I-R91150 in healthy volunteers: Part 2 - Ketanserin displacement. J Nucl Med 47, 929-937 (2006)
  • Deng WP, Wu CC, Lee CC, Yang WK, Wang HE, Liu RS, Wei HJ, Gelovani JG, Hwang JJ, Yang DM, Fu YK, Wu CW. Serial in vivo imaging of the lung metastases model and gene therapy using HSV1-tk and ganciclovir. J Nucl Med 47, 877-884 (2006)
  • Gielow P, Klinge P, Knapp WH, Berding G. Synthesis and preliminary biological evaluation of [123I]Me2Pyr, a new potential ligand for imaging of central cannabinoid CB, receptors. Appl Radiat Isot 64, 763-768 (2006)
  • Hirata M, Mori T, Soga S, Umeda T, Ohmomo Y. Synthesis and in vitro evaluation of iodinated derivatives of piperazine as a new ligand for σ receptor imaging by single photon emission computed tomography. Chem Pharm Bull Tokyo 54, 470-475 (2006)
  • Kanegawa N, Kiyono Y, Kimura H, Sugita T, Kajiyama S, Kawashima H, Ueda M, Kuge Y, Saji H. Synthesis and evaluation of radioiodinated (S,S)-2(α-(2-iodophenoxy)benzyl)morpholine for imaging brain norepinephrine transporter. Eur J Nucl Med Mol Imaging 33, 639-647 (2006)
  • Millet P, Graf C, Moulin M, Ibanez V. SPECT quantification of benzodiazepine receptor concentration using a dual-ligand approach. J Nucl Med 47, 783-793 (2006)
  • Newberg AB, Wintering NA, Plossl K, Hochold J, Stabin MG, Watson M, Skovronsky D, Clark CM, Kung MP, Kung HF. Safety, biodistribution, and dosimetry of 123I-IMPY: A novel amyloid plaque-imaging agent for the diagnosis of Alzheimer's disease. J Nucl Med 47, 748-754 (2006)
  • Ni Y, Huyghe D, Verbeke K, De Witte PA, Nuyts J, Mortelmans L, Chen F, Marchal G, Verbruggen AM, Bormans GM. First preclinical evaluation of mono-[123I]iodohypericin as a necrosis-avid tracer agent. Eur J Nucl Med Mol Imaging 33, 595-601 (2006)
  • Niu G, Anderson RD, Madsen MT, Grahame MM, Oberley LW, Domann FE. Dual-expressing adenoviral vectors encoding the sodium iodide symporter for use in noninvasive radiological imaging of therapeutic gene transfer. Nucl Med Biol 33, 391-398 (2006)
  • Ogawa M, Tatsumi R, Fujio M, Katayama J, Magata Y. Synthesis and evaluation of [125I]I-TSA as a brain nicotinic acetylcholine receptor α7 subtype imaging agent. Nucl Med Biol 33, 311-316 (2006)
  • Oltenfreiter R, Staelens L, Kersemans V, Cornelissen B, Frankenne F, Foidart JM, Van de Wiele C, Slegers G. Valine-based biphenylsulphonamide matrix metalloproteinase inhibitors as tumor imaging agents. Appl Radiat Isot 64, 677-685 (2006)
  • Shankar S, Zalutsky MR, Friedman H, Vaidyanathan G. Molecular imaging of alkylguanine-DNA alkyltransferase: Further evaluation of radioiodinated derivatives of O-6-benzylguanine. Nucl Med Biol 33, 399-407 (2006)
  • Steffen AC, Orlova A, Wikman M, Nilsson FY, Stahl S, Adams GP, Tolmachev V, Carlsson J. Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice. Eur J Nucl Med Mol Imaging 33, 631-638 (2006)
  • Yu CS, Chiang LW, Wu CH, Wang RT, Chen SW, Wang HY, Yeh CH. Synthesis of 5-radioiodoarabinosyl uridine analog for probing HSV-1 thymidine kinase gene: An unexpected chelating effect. Nucl Med Biol 33, 367-370 (2006)
  • 14. Technetium
  • Ballot S, Noiret N, Hindre F, Denizot B, Garin E, Rajerison H, Benoit JP. 99mTc/188Re-labelled lipid nanocapsules as promising radiotracers for imaging and therapy: Formulation and biodistribution. Eur J Nucl Med Mol Imaging 33, 602-607 (2006)
  • Blankenberg FG, Kalinyak J, Liu LP, Koike M, Cheng DY, Goris ML, Green A, Vanderheyden JL, Tong DC, Yenari MA. 99mTc-HYNIC-annexin VSPECT imaging of acute stroke and its response to neuroprotective therapy with anti-Fas ligand antibody. Eur J Nucl Med Mol Imaging 33, 566-574 (2006)
  • Chen LB, Altman A, Mier W, Lu HK, Zhu RS, Haberkorn U. 99mTc-pertechnetate uptake in hepatoma cells due to tissue-specific human sodium iodide symporter gene expression. Nucl Med Biol 33, 575-580 (2006)
  • Chen Y, Huang ZW, He L, Zheng SL, Li JL, Qin DL. Synthesis and evaluation of a technetium-99m-labeled diethylenetriaminepentaacetatedeoxyglucose complex ([99mTc]-DTPA-DG) as a potential imaging modality for tumors. Appl Radiat Isot 64, 342-347 (2006)
  • Cooper M, Dustan K, Rotureau L. The effect on radiochemical purity of modifications to the method of preparation and dilution of 99mTc-sestamibi. Nucl Med Commun 27, 455-460 (2006)
  • Fan CY, Jia HM, Deuther-Conrad W, Brust P, Steinbach J, Liu BL. Novel 99mTc labeled σ receptor ligand as a potential tumor imaging agent. Sci China B 49, 169-176 (2006)
  • James S, Maresca KP, Babich JW, Valliant JF, Doering L, Zubieta J. Isostructural Re and 99mTc complexes of biotin derivatives for fluorescence and radioimaging studies. Bioconjug Chem 17, 590-596 (2006)
  • Khaw BA, Tekabe Y, Johnson LL. Imaging experimental atherosclerotic lesions in ApoE knockout mice: Enhanced targeting with Z2D3-anti-DTPA bispecific antibody and 99mTc-labeled negatively charged polymers. J Nucl Med 47, 868-876 (2006)
  • Kim EM, Jeong HJ, Kim SL, Sohn MH, Nah JW, Bom HS, Park IK, Cho CS. Asialoglycoprotein-receptor-targeted hepatocyte imaging using 99mTc galactosylated chitosan. Nucl Med Biol 33, 529-534 (2006)
  • Kim YS, Hea ZJ, Schibli R, Liu S. Synthesis, characterization and X-ray crystal structure of [Re(L4)(CO)3]Br.2CH3OH (L4=N,N-bis[(2-diphenylphosphino)ethyl]-methoxyethylamine): A model compound for novel cationic 99mTc(I)-tricarbonyl radiotracers useful for heart imaging. Inorg Chim Acta 359, 2479-2488 (2006)
  • Lipowska M, He HY, Malveaux E, Xu XL, Marzilli LG, Taylor A. First evaluation of a 99mTc-tricarbonyl complex, 99mTc(CO)3(LAN), as a new renal radiopharmaceutical in humans. J Nucl Med 47, 1032-1040 (2006)
  • Liu S, He ZJ, Hsieh WY, Kim YS. Evaluation of novel cationic 99mTc-nitrido complexes as radiopharmaceuticals for heart imaging: Improving liver clearance with crown ether groups. Nucl Med Biol 33, 419-432 (2006)
  • Mallia MB, Mathur A, Subramanian S, Banerjee S, Kothari K, Koiry SP, Sarma HD, Venkatesh M. Synthesis and evaluation of ether containing 99mTc-nitrido dithiocarbamate complexes as brain perfusion imaging agent. Appl Radiat Isot 64, 361-367 (2006)
  • Mathur A, Mallia MB, Subramanian S, Banerjee S, Sarma HD, Kothari K, Venkatesh M. Preparation and in vivo evaluation of 99mTcN-tertiary butyl xanthate as a potential myocardial agent. Appl Radiat Isot 64, 663-667 (2006)
  • Palumbo B, Lupattelli M, Pelliccioli GP, Chiarini P, Moschini TO, Palumbo I, Siepi D, Buoncristiani P, Nardi M, Giovenali P, Palumbo R. Association of 99mTc-MIBI brain SPECT and proton magnetic resonance spectroscopy (1H-MRS) to assess glioma recurrence after radiotherapy. Q J Nucl Med Mol Imaging 50, 88-93 (2006)
  • Schommartz B, Cupisti K, Antke C, Schmidt D, Knoefel WT, Muller HW. Localisation of parathyroid glands using planar 99mTc-sestamibi scintigraphy - Comparison between subtraction- and dual-phase technique (German, English Abstract). Nuklearmedizin 45, 115-121 (2006)
  • Zhang KJ, An R, Gao ZR, Zhang YX, Aruva MR. Radionuclide imaging of small-cell lung cancer (SCLC) using 99mTc-labeled neurotensin peptide 8-13. Nucl Med Biol 33, 505-512 (2006)
  • 15. Others
  • Arias-Mendoza F, Payne GS, Zakian KL, Schwarz AJ, Stubbs M, Stoyanova R, Ballon D, Howe FA, Koutcher JA, Leach MO, Griffiths JR, Heerschap A, Glickson JD, Nelson SJ, Evelhoch JL, Charles HC, Brown TR. In vivo31P MR spectral patterns and reproducibility in cancer patients studied in a multi-institutional trial. NMR Biomed 19, 504-512 (2006)
  • Bendahan D, Mattei JP, Guis S, Kozak-Ribbens G, Cozzone PJ. Non invasive investigation of muscle function using 31P magnetic resonance spectroscopy and 1H MR imaging (French, English Abstract). Rev Neurol (Paris) 162, 467-484 (2006)
  • Catalaa I, Henry R, Dillon WP, Graves EE, McKnight TR, Lu Y, Vigneron DB, Nelson SJ. Perfusion, diffusion and spectroscopy values in newly diagnosed cerebral gliomas. NMR Biomed 19, 463-475 (2006)
  • Gheysens O, Lin S, Cao F, Wang DX, Chen IY, Rodriguez-Porcel M, Min JJ, Gambhir SS, Wu JC. Noninvasive evaluation of immunosuppressive drug efficacy on acute donor cell survival. Mol Imaging Biol 8, 163-170 (2006)
  • Gillies JM, Prenant C, Chimon GN, Smethurst GJ, Perrie W, Hambletta I, Dekker B, Zweit J. Microfluidic reactor for the radiosynthesis of PET radiotracers. Appl Radiat Isot 64, 325-332 (2006)
  • Gillies JM, Prenant C, Chimon GN, Smethurst GJ, Dekker BA, Zweit J. Microfluidic technology for PET radiochemistry. Appl Radiat Isot 64, 333-336 (2006)
  • Ishikawa TO, Jain NK, Taketo MM, Herschman HR. Imaging cyclooxygenase-2 (Cox-2) gene expression in living animals with a luciferase knock-in reporter gene. Mol Imaging Biol 8, 171-187 (2006)
  • Jalilian AR, Rowshanfarzad P, Sabet M, Shafiee A. Preparation of [61Cu]-2-acetylpyridine thiosemicarbazone complex as a possible PET tracer for malignancies. Appl Radiat Isot 64, 337-341 (2006)
  • Jensen JE, Miller J, Williamson PC, Neufeld RWJ, Menon RS, Malla A, Manchanda R, Schaefer B, Densmore M, Drost DJ. Grey and white matter differences in brain energy metabolism in first episode schizophrenia: 31P-MRS chemical shift imaging at 4 Tesla. Psychiatr Res Neuroimaging 146, 127-135 (2006)
  • Kingsley PB, Shah TC, Woldenberg R. Identification of diffuse and focal brain lesions by clinical magnetic resonance spectroscopy. NMR Biomed 19, 435-462 (2006)
  • Maudsley AA, Darkazanli A, Alger JR, Hall LO, Schuff N, Studholme C, Yu Y, Ebel A, Frew A, Goldgof D, Gu Y, Pagare R, Rousseau F, Sivasankaran K, Soher BJ, Weber P, Young K, Zhu X. Comprehensive processing, display and analysis for in vivo MR spectroscopic imaging. NMR Biomed 19, 492-503 (2006)
  • Nakao R, Furutuka K, Yamaguchi M, Suzuk K. Quality control of PET radiopharmaceuticals using HPLC with electrochemical detection. Nucl Med Biol 33, 441-447 (2006)
  • Payne GS, Troy H, Vaidya SJ, Griffiths JR, Leach MO, Chung YL. Evaluation of 31P high-resolution magic angle spinning of intact tissue samples. NMR Biomed 19, 593-598 (2006)
  • Rowland DJ, Tu ZD, Xu JB, Ponde D, Mach RH, Welch MJ. Synthesis and in vivo evaluation of 2 high-affinity 76Br-labeled σ2-receptor ligands. J Nucl Med 47, 1041-1048 (2006)
  • Shoghi-Jadid K, Barrio JR, Kepe V, Huang SC. Exploring a mathematical model for the kinetics of β-amyloid molecular imaging probes through a critical analysis of plaque pathology. Mol Imaging Biol 8, 151-162 (2006)
  • Yang YS, Zhang XZ, Xiong ZM, Chen XY. Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma. Nucl Med Biol 33, 371-380 (2006)
  • Yuan H, Schroeder T, Bowsher JE, Hedlund LW, Wong T, Dewhirst MW. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis (N-4-methylthiosemicarbazone). J Nucl Med 47, 989-998 (2006)
  • Zhu XP, Schuff N, Kornak J, Soher B, Yaffe K, Kramer JH, Ezekiel F, Miller BL, Jagust WJ, Weiner MW. Effects of Alzheimer disease on fronto-parietal brain N-acetyl aspartate and myo-inositol using magnetic resonance spectroscopic imaging. Alzheimer Dis Assoc Disord 20, 77-85 (2006)
Get PDF (178K)